{"id":"blinatumomab-plus-reduced-dose-chemotherapy","safety":{"commonSideEffects":[{"rate":"44%","effect":"Neutropenia"},{"rate":"34%","effect":"Anemia"},{"rate":"29%","effect":"Thrombocytopenia"},{"rate":"26%","effect":"Leukopenia"},{"rate":"24%","effect":"Infections"},{"rate":"22%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"18%","effect":"Diarrhea"},{"rate":"16%","effect":"Vomiting"},{"rate":"15%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Blinatumomab is a bispecific monoclonal antibody that binds to CD19 on B cells and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.","oneSentence":"Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:53.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute Lymphoblastic Leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT03480438","phase":"PHASE2","title":"Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab","status":"COMPLETED","sponsor":"Goethe University","startDate":"2018-06-01","conditions":"B-Precursor ALL","enrollment":52},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT06061094","phase":"PHASE2","title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","status":"RECRUITING","sponsor":"Goethe University","startDate":"2023-07-14","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT06742515","phase":"PHASE2","title":"Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-17","conditions":"Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT06649422","phase":"","title":"Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2024-11-01","conditions":"Leukemia, Lymphocytic, Acute, Adult","enrollment":36},{"nctId":"NCT05557110","phase":"PHASE2","title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","status":"COMPLETED","sponsor":"Chen Suning","startDate":"2022-09-08","conditions":"B Acute Lymphoblastic Leukemia","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Blinatumomab plus Reduced-dose Chemotherapy","genericName":"Blinatumomab plus Reduced-dose Chemotherapy","companyName":"Xianmin Song, MD","companyId":"xianmin-song-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies. Used for Acute Lymphoblastic Leukemia (ALL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}